Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | Evaluating germline variant GFI1-36N and its impact on DNA repair in AML

Cyrus Khandanpour • 20 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia

In this video, Cyrus Khandanpour MD, PhD, University Hospital of Schleswig-Holstein, Lübeck, Germany, discusses research into the germline variant GFI1-36N and its impact on patient response to therapy in acute myeloid leukemia (AML). Results demonstrated that this variant is involved in DNA repair and may present an opportunity for targeted therapy. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals